Cariprazine is a recently developed antipsychotic drug with a partial agonism for the D2 and D3 receptors. It shows a tenfold greater affinity for the D3 receptor. In clinical trials, its therapeutic effect has been tested in patients with an acute exacerbation of schizophrenia and in patients with acute mania in bipolar disorder. Like risperidone, cariprazine improves positive and negative sch...

View Large Image Figure ViewerDownload Hi-res image Download (PPT)View (PPT) Research is limited regarding the prevalence of drug-induced movement disorders in residents long-term care (LTC) facilities. By contrast, there extensive literature documenting that this population typically at a higher risk for disorders: both median age LTC and increased use pharmacological interventions contribute ...

BACKGROUND Schizophrenia is a chronic and debilitating neuropsychiatric disorder that often requires long-term pharmacotherapy to manage symptoms and prevent relapse. Cariprazine is a potent dopamine D3 and D2 receptor partial agonist that is FDA-approved in the US for the treatment of schizophrenia and manic or mixed episodes associated with bipolar I disorder in adults; the recommended dose r...

Although haloperidol (HAL)has been available as an antipsychotic for over 30 years, controversy still surrounds the appropriate dose in the treatment of psychosis and in particular, schizo phrenia. In practice, high dose HAL (greater than 20 mg/day) continues to be prescribed, despite good reason for not doing so: the incidence of extrapyramidal side-effects (EPSE) is known to be dose-related; ...

The authors found a 31% incidence of tardive dyskinesia among 261 schizophrenic outpatients treated with neuroleptics. Multiple linear logistic regression analysis revealed a higher incidence of tardive dyskinesia among elderly patients, those with longer records of hospitalization, those for whom neuroleptic medication had little therapeutic effect, and those treated with fluphenazine. Patient...

Bluym I, Munitz H, Shalev A, Roberts E (1984): Naloxone may be beneficial in the treatment of tardive dyskinesia. C l i n Neuropharmacol 7:265-267. Brambilla F, Facchinetti F, Petraglia F, et al (1984): Secretion patterns of endogenous opioids in chronic schizophrenia. Am J Psychiatry 141:1183-1189. Cuello AC (1983): Central distribution of opioid peptides. Br Med Bull 39:11-16. Gillman MA, San...